

Press release

One Biosciences and Gustave Roussy join forces on a research project to fight bladder cancer.

Paris, France, April 09, 2024 – Gustave Roussy has joined forces with One Biosciences, a biotechnology company that leverages the power of single-cell analysis and AI to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat conditions. This research project focuses on bladder cancer, to better adapt therapeutic strategies to patients suffering from this disease.

In this unique and wide-ranging research partnership, Gustave Roussy is providing One Biosciences with anonymised data from 36 patients, offering a particularly valuable source of information. In turn, One Biosciences will use its discovery engine composed single-cell technologies and AI models and meets the highest standards in terms of security and control of all patient medical data to provide a better understanding of the mechanisms of resistance to immunotherapy identified in some patients. Immunotherapy is indeed the standard of care for the treatment of bladder cancer.

One Biosciences, created by Institut Curie and venture builder Home Biosciences, is housed at Biolabs Hôtel-Dieu, a start-up ecosystem set up by the AP-HP and the University of Paris to develop a place of open innovation in healthcare, connected to a network of 39 hospitals in Paris. This announcement marks the start of a long-term partnership between One Biosciences and Gustave Roussy, which will drive the emergence of new solutions and technologies for cancer patients.

Dr. Yohann Lorient, Deputy Head of the Department of Therapeutic Innovation and Early Trials at Gustave Roussy said: *"We are very pleased with this collaboration, which leverages a brand new way of analysing complex biological data. We aim to identify new therapeutic approaches in a difficult-to-treat cancer and expand into other cancers with this landmark innovation".*

Hedi Ben Brahim, CEO of One Biosciences said: *"This partnership illustrates once again the dynamism of the French innovation ecosystem and the emerging private and public synergies. After forging strategic partnerships with Institut Curie and the AP-HP, One Biosciences is now joining forces with Gustave Roussy to accelerate research into the causes of resistance to bladder cancer treatment. We aim to identify potential therapeutic targets to meet a major need among patients with no satisfactory treatment options. This is a landmark achievement, and I would like to thank our partners for their commitment".*

About bladder cancer

Bladder cancer is the 7th most common cancer, with around 13,000 new cases each year in France (2018 INCa figures). Disease of the cells in the inner lining of the bladder,

it develops itself from a normal cell that changes, then multiplies in an uncontrolled way until it forms a tumour. Bladder cancer affects men more than women. It is the most common urological cancer after prostate cancer.

About Gustave Roussy

Ranked first in France, first in Europe and fourth in the world, Gustave Roussy is a centre of global expertise entirely dedicated to patients living with cancer. The Institute is a founding keystone of the Paris-Saclay Cancer Cluster. Being a source of therapeutic innovations and diagnostic advances, the Institute cares for almost 50,000 patients every year, including 3,500 children and adolescents, and develops an integrated approach between research, care and teaching. As an expert in rare cancers and complex tumours, Gustave Roussy treats all cancers at all stages of life. It provides its patients with personalised care that combines innovation and humanity, considering not only treatment but also physical, psychological and social quality of life. With 4,100 employees on two sites, Villejuif and Chevilly-Larue, Gustave Roussy brings together the expertise required for top-level cancer research; 40% of patients treated are included in clinical trials.

To find out more about Gustave Roussy and keep up with the latest news from the Institute: www.gustaveroussy.fr, [Twitter](#), [Facebook](#), [LinkedIn](#), [Instagram](#)

Press contact: Claire Parisel – +33 1 42 11 50 59 – +33 6 17 66 00 26 – claire.parisel@gustaveroussy.fr

About One Biosciences

One Biosciences leverages the power of single cell analysis and AI to identify a new wave of precision medicine targets and treatments across a broad range of diseases that are difficult to treat. One Biosciences is an integrated discovery ecosystem, supported by a multidisciplinary team with computational capabilities. One Biosciences is supported by the Institut Curie and Home Biosciences.

For further information: www.onebiosciences.fr

Contact: contact@onebiosciences.fr

Europe Press Contact – Taddeo:

Julia Friedlander – julia.friedlander@taddeo.fr – 06 83 00 97 55

Marie Gesquière – marie.gesquiere@taddeo.fr – 06 28 22 97 58